Algernon Pharmaceuticals Inc (AGNPF)

[Money $hot]

Dilution to make your head spin. Long shares are about to get raked over the coals beyond the 2 to 1 and 100 to 1 reverse splits.

Offering Price lowered and Shares/Warrants increased. Additional 500,000 Shares + 500,000 Warrants for public offering and underwriters. 8M Capital Raise to 8.4M Capital Raise.

Total Shares + Warrants up for grabs - 4,363,984

Current Outstanding Shares - 1,674,868

Current Warrants - 527,770

Outstanding Shares after public offering - 3,856,860

Warrants after public offering - 2,709,762

Fully Diluted Shares - 6,566,622


Form F1/A
Amendment #4 - Filed April 25 2022

1,684,210 Units, each Unit Consisting of One Common Share and one Warrant to Purchase one Common Share

1,684,210 Pre-funded Units, each Pre-funded Unit Consisting of one Pre-Funded Warrant to Purchase one Common Share and one Warrant to Purchase one Common Share

We will sell these Units at a public offering price of US$4.75 per Unit.

Each Warrant will entitle the holder to purchase one Common Share at an exercise price of 110% of the price of the Units in this offering

https://www.sec.gov/Archives/edgar/data/0001642178/000106299322010694/formf1a.htm


Form F1/A
Amendment #5 - Filed May 9 2022

In December 2021, we became a remote-first company. Accordingly, we do not currently maintain a headquarters.

1,931,922 Units, each Unit Consisting of One Common Share and one Warrant to Purchase one Common Share

1,931,922 Pre-funded Units, each Pre-funded Unit Consisting of one Pre-Funded Warrant to Purchase one Common Share and one Warrant to Purchase one Common Share

...based on an assumed offering price per Unit of US$4.348, the last reported price of our Common Shares as reported on the OTC Market Group Inc.'s Venture Market (the "OTCQB") on May 5, 2022. Each Warrant will entitle the holder to purchase one Common Share at an exercise price of 110% of the price of the Units in this offering

We have granted the underwriters a 45-day option (commencing from the date of this Prospectus) to purchase up to an additional 289,788 Common Shares and/or up to an additional 289,788 Warrants at the public offering price per Common Share and per Warrant respectively

https://www.sec.gov/Archives/edgar/data/0001642178/000106299322011852/formf1a.htm


FWP (Prospectus) - Filed May 10 2022

https://www.sec.gov/Archives/edgar/data/0001642178/000106299322011950/formfwp.htm

A free writing prospectus (FWP) is a written communication regarding securities being publicly offered disseminated by the issuer during the waiting period of an initial public offering (IPO) that discloses information that would not be included in the registration statement.

https://www.law.cornell.edu › wex

M$ comment:

Longs holding pre-split shares will need a Market Cap of $200M USD to break even. Basically dead money here for the foreseeable future. As I see nothing in the pipeline to get to that valuation prior to a standalone clinical trial for Chronic Cough with stat SIG results better than Bellus Health. Meanwhile, the walls around Algernon appear to be on fire but for the fact the company no longer has a corporate office. Pure insanity with Moreau's prior BS decisions and timelines driving the company over every cliff imaginable. Moreau stated his goal was to provide shareholders with "Life-changing" returns on their investment. Uhh ok. In what lifetime - this one or the next? A standalone Chronic Cough Phase 3 clinical trial should already be underway. It's the best shot at success purchased by shareholders back in 2018. Christopher Moreau is unequivocally the absolute worst "CEO" ever.

Stay tuned

https://algernonpharma.com/